Revenue from Blueprint’s rare-disease drug topped fourth-quarter expectations, but BPMC stock could topple on its light outlook for the year.

The post Blueprint Medicines Outranks 92% Of All Stocks. But This Could Be Its Undoing. appeared first on Investor’s Business Daily.